Personalized breast cancer screening could revolutionize how millions of women approach preventive care, moving beyond the one-size-fits-all annual mammography model toward individualized risk assessment. This shift represents a fundamental rethinking of screening protocols that have remained largely unchanged for decades. The JAMA Network randomized clinical trial evaluated whether tailoring mammography frequency to individual risk profiles delivers comparable or superior cancer detection while reducing unnecessary procedures and healthcare costs. Women aged 40 and older were stratified based on personal and family history, genetic markers, breast density, and other established risk factors. Those deemed lower-risk received less frequent screening, while higher-risk participants maintained or increased their screening intervals. The study tracked detection rates, stage at diagnosis, and interval cancers across both approaches. Initial findings suggest risk-stratified protocols can maintain detection efficacy while substantially reducing false positives and patient anxiety associated with routine annual screening. The personalized approach identified comparable numbers of clinically significant cancers while dramatically decreasing callbacks for benign findings. However, several critical limitations temper immediate clinical adoption. The study duration may be insufficient to capture long-term outcomes, particularly for slower-growing tumors that annual screening might detect earlier. Risk stratification tools, while improving, still carry inherent uncertainties in prediction accuracy. Healthcare systems would require substantial infrastructure changes to implement individualized protocols effectively. This research represents an incremental but meaningful step toward precision medicine in breast cancer prevention, though widespread implementation will require additional validation studies and careful consideration of healthcare equity implications.